CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 381 enrolled
Drug / intervention
ABT-450/r/ABT-267, ABT-333 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01704755
NCT01704755Phase 3Completed
CompareCT.gov

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)

AbbVie (prior sponsor, Abbott)·interventional·Posted Oct 11, 2012·Updated Jul 12, 2021

In Brief

A Phase 3 clinical trial evaluating ABT-450/r/ABT-267, ABT-333 and Ribavirin (RBV) for Chronic Hepatitis C Infection and Compensated Cirrhosis. Completed, enrolled 381 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) coadministered with ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-infected adults with compensated cirrhosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Infection, Compensated Cirrhosis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 11, 2012
Enrollment StartOct 1, 2012
Primary CompletionJan 1, 2014
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.7 years ago

Interventions

ABT-450/r/ABT-267, ABT-333drug

Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet

Ribavirin (RBV)drug

Capsule